Abbott Zyflo "homemade" step-down dosing promotional materials cited by FDA in June 27 letter.
ABBOTT ZYFLO "HOMEMADE" STEP-DOWN DOSING PROMOTIONAL MATERIALS CITED by FDA in a June 27 letter to the company. The Division of Drug Marketing, Advertising, & Communications "has received information about various promotional claims, including unapproved Zyflo [zileuton] dosage regimens (i.e., step-down dosing) and unsubstantiated efficacy claims, allegedly being disseminated by Abbott sales representatives in widely varied geographic areas of the U.S.," FDA told the company.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth